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transplantation. Perfusion characteristics were studied in 47 liver perfusions, of
which22resultedintransplants.Hepatocellulardamagewasreflectedintheperfu‐
sate transaminase concentrations, which correlated with posttransplant peak









viability during normothermic perfusion can be assessed using a combination of
transaminase release, glucose metabolism, lactate clearance, and maintenance of
acid-basebalance.EvaluationofbilepHmayofferavaluable insight intobileduct
integrityandriskofposttransplantischemiccholangiopathy.
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1  | INTRODUC TION
Reliablemetrics todeterminewhethera liver isviableandsafe to
transplant are currently not available.Normothermic perfusion of
the liveraffordsanopportunity forviabilityassessment.Although
therehavebeen case reports and small series of liver transplants
followingexsitunormothermicperfusion,1–5thereareasyetnoval‐
idatedcriteriapredictingliverviability.
This paper describes our observations on the biochemistry
and perfusion characteristics of 47 human livers thatwere nor‐
mothermicallyperfused,ofwhich22weretransplanted.Weused
readily available biochemical and physical measurements that
couldbeanalyzedduringperfusion.Fromthesestudies,wehave
demonstratedcriteriathatmaybehelpful indeterminingviability
and identified others that are not as discriminatory as has been
suggested.5,6




by perfusion prior to implantation, were included. All were pre‐
served initially with University of Wisconsin static cold storage
solution.
Approvals from the local research ethics committee and the






2.2 | Normothermic ex situ liver perfusion (NESLiP)
Livers were perfused using the Liver Assist (Organ Assist,








commenced at 20°C for all livers; the perfusatewaswarmed to
TABLE  1 Protocolevolutionduringstudy
Research livers 







Perfusatecolloid Gelofusine Steensolution Gelofusine















Perfusatecolloid Gelofusine Steensolution Gelofusine
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The glycogen content of frozen right lobe liver biopsieswas esti‐
mated using Zhang’s adaptation of an acid hydrolysis method.8,9 
Briefly, liver biopsies were homogenized with either sodium hy‐
droxideorhydrochloricacid.Thesupernatantwasthenmixedwith











A total of47 livers, 12 frombraindead (DBD) and35 fromcir‐
culatory death (DCD) donors, were subject to NESLiP (Table2)
betweenJanuary2014andOctober2017.Ofthe28liversaccepted
forpossibletransplantation,20weretransplantedwhile2ofthe
19 livers acceptedwithno intent to transplantwerealso trans‐




viously.7 One recipient died following primary nonfunction (T6),
one (T12) developed early allograft dysfunction byOlthoff’s cri‐
teria (day7INR1.6),11and4recipientshavedevelopedischemic-
typebiliarylesions(ITBL)at33to89daysposttransplantofwhom
3 required retransplantation.None of the last 16 cases suffered
reperfusionsyndromeorvasoplegia,somethingthataffectedcases
T2toT6.7













ALTconcentrationsweremeasured in theeffluentof28 livers
afterflushingwithcompoundsodiumlactate(Hartmann’s)solution
prior toNESLiP. The effluentALTwas correlatedwith theALTof
the perfusate 2hours after starting NESLiP (Figure3A, r=.78,
P<.0001; AST r=.649, P=.031). Similar data were obtained for







The baseline lactate concentration varied and was higher in livers
flushedwithHartmann’s solution (Figure4).Fifteen livers (32%)ex‐
hibitedaninitialriseinlactatewithinthefirst30minutesofNESLiP
beforefalling.Theconcentrationfelltobelow2.5mmol/Lby180min‐








the glucose subsequently fell, the peakwas reachedby2hours.
The rate of fall varied between 0.67 and 3.8mmol/L/kg/h, ap‐
pearedtofollowzeroorderkinetics,andwas independentof in‐
sulin, whether given as continuous infusion or as boluses of up
150units(datanotshown).Insulinwasthereforeomittedfromthe
last35NESLiPs.



























Max rate of lactate fallb
Amount of 
NaCO3 added in 
first 4 h (mmol)
Perfusate glucose 
(mmol/L)




















T1 DCD 57 T 10 160 360 2.01 1.98 G 1365 9.3 — 20 18.8 — Notchecked None
T2 DCD 24 T 5 17 419 1.92 1.45 G 1315 6.0 — 10 15.0 3.7 Notchecked None
T3 DCD 57 T 30 41 346 2.09 1.91 G 1920 7.6 — 25 5.9 8.1 Notchecked IC Awaitingretransplant
T4 DCD 63 T 20 31 222 2.08 2.09 G 1478 10.5 — 20 22.5 19.9 Notchecked None
T5 DCD 45 T 17 31 445 2.12 1.69 G 3783 9.2 — 30 >40 27.0 7.56 7.17 Notchecked None
T6 DCD 48 T 14 36 438 2.45 2.35 S 9490 4.6 — 35 9.5 8.6 Notchecked None Primarynonfunction
T7 DCD 55 T 11 30 396 2.51 2.03 S 1947 10.1 — 0 26.6 20.1 6.89 7.31 23.4 24.7 IC
T8 DBD 60 T 0 0 608 2.17 1.01 S 5576 10.6 — 0 31.5 24.0 7.85 7.30 3.5 20.5 None
T9 DCD 58 R 5 37 389 3.14 1.99 G 1118 21.5 11.6 40 38.4 30.1 7.57 7.24 7.0 22.0 None Researchofferbecauseoftraumaticinjurytoleft
lobe,mildlyfattyand“long”withdrawaltime
T10 DBD 39 R 0 0 618 1.47 0.96 G 418 14.0 13.3 0 8.5 6.3 7.84 7.20 1.8 14.1 None Researchofferbecauseofpoorinsituperfusion
T11 DCD 54 T 12 24 435 2.81 2.53 G 913 7.2 5.5 0 31.0 — 7.29 7.23 29.2 31.0 IC Retransplantd188forIC
T12 DBD 67 T 0 0 877 2.44 1.75 G 555 9.2 7.1 5 20.8 — Insufficientbile None Earlyallograftdysfunction:INR1.6onday7.
T13 DBD 71 T 0 0 245 2.00 1.15 G 4828 10.2 6.6 10 19.6 19.6 7.74 7.29 2.2 19.3 None
T14 DCD 69 T 10 51 383 3.57 2.20 G 486 11.7 16.3 0 9.4 7.9 7.69 7.48 Noreading None
T15 DBD 41 T 0 0 321 1.46 1.08 G 1377 10.1 6.2 5 14.4 — 7.53 7.07 Noreading None
T16 DCD 67 T 14 24 333 3.66 2.92 G 1753 7.7 5.8 5 12.1 13.8d 7.31 7.25 Noreading IC Retransplantday107forICandHAT
T17 DCD 43 T 12 23 330 2.67 1.95 G 1506 6.0 4.4 15 23.3 19.4 7.92 7.17 9.1 21.9 None
T18 DCD 66 T 13 24 448 3.17 2.24 G 2318 9.3 5.9 15 14.4 16.7d 7.72 7.23 2.6 15.5 None
T19 DCD 55 T 11 33 439 2.85 2.55 G 262 11.6 15.2 10 15.9 16.4 7.66 7.25 5.6 15.7 None
T20 DCD 29 T 10 16 292 1.69 1.43 G 216 12.6 5.6 15 18.6 17.4 7.62 7.39 2.1 18.7 None
T21 DBD 64 T 0 0 354 2.12 1.6 G 1906 9.0 8.1 10 17.5 18.3 7.89 7.28 3.8 18.3 None
T22 DCD 69 T 12 35 327 4.12 2.62 G 1631 5.8 4.9 10 21.6 15.7 7.72 7.27 5.8 13.4 None
R1 DCD 52 R 10 16 539 2.21 1.77 G 3561 7.8 — 20 8.3 8.2 Notchecked
R2 DCD 34 R 13 20 913 2.71 2.02 G 4385 3.8 4.2 0 22.8 — Notchecked
R3 DCD 39 R 16 27 523 1.69 1.39 G 8076 10.4 5.6 60 37.0 35.3 Notchecked
R4 DCD 46 R 12 420 264 1.84 1.42 G 3686 15.9 — 0 15.9 — Notchecked
R5 DBD 55 R 0 0 600 1.70 1.19 S 2561 15.0 10.3 15 33.8 — Notchecked
R6 DCD 64 R 10 21 384 3.60 2.26 S 740 6.7 4.1 5 24.6 18.5 Notchecked
R7 DCD 44 R 9 22 574 1.70 2.01 S 11970 10.7 5.5 0 14.7 12.2 Notchecked
R8 DCD 45 R 12 38 836 2.99 1.64 G 8348 6.8 4.5 0 10.6 7.2 Insufficientbile
R9 DCD 76 R 12 ? 611 3.14 2.38 G 1573 17.2 9.4 0 28.1 23.9 Insufficientbile
R10 DCD 44 R 8 12 261 2.11 2.02 G 2469 3.5 2.7 30 20.6 17.2 Noreading
R11 DCD 61 T 12 18 456 2.78 2.21 G 4616 6.2 4.0 10 18.5 — Insufficientbile 3 Nottransplanted:Leftlobenotperfuseddueto
dividedleftaccessoryhepaticartery
R12 DCD 69 R 11 21 764 2.70 2.60 G 3623 16.9 13.6 0 28.0 21.4 7.72 7.42 5.4 23.7 1 Unexplainedleftlobeatrophy
R13 DBD 44 R 0 0 1148 1.92 0.97 G 7254 8.8 4.2 20 34.8 27.4 7.38 7.22 32.2 32.6 4 Verysteatoticliver
R14 DCD 35 T 13 20 323 1.74 1.65 G 2648 12.4 8.3 0 15.8 — 7.47 7.10 6.4 14.2 4 NottransplantedduetolowbilepH
R15 DCD 47 R 11 11 686 2.62 1.71 G 5386 7.5 4.8 30 26.7 24.5 Hemobilia 1 Cysticductnotligated.Steatohepatitisonbiopsy
R16 DCD 66 T 8 26 518 3.31 1.91 G 2439 8.7 4.2 40 37.6 35.9 7.40 7.33 34.5 35.9 3/4 Nottransplanted:Poorglucosefall,slowlactatefall,
risingpotassiumandhighbicarbonateuse,lowbilepH
R17 DBD 81 R 0 0 466 2.37 1.71 G 346 12.3 11.5 0 23.4 28.8 Hemobilia 2
R18 DCD 49 T 11 30 482 2.81 1.81 G 694 17.3 10.1 15 21.1 18.5 7.31 7.19 18.3 21.9 4 Nottransplanted,lowbilepH
R19 DCD 59 T 12 32 306 2.68 1.97 G 4909 10.4 10 30.1 20.9 7.44 7.21 24.7 28.2 4 Nottransplanted,lowbilepH
R20 DBD 55 T 0 0 328 1.79 0.99 G 4294 6.8 3.0 20 16.6 9.8d 7.46 7.27 4.1 8.6 2 Nottransplanted,lowbilepH
R21 DCD 57 R 28 ? 467 3.36 2.49 G 4852 6.7 4.6 15 22.3 14.9 7.75 7.21 15.5 14.9 1
(Continues)
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T1 DCD 57 T 10 160 360 2.01 1.98 G 1365 9.3 — 20 18.8 — Notchecked None
T2 DCD 24 T 5 17 419 1.92 1.45 G 1315 6.0 — 10 15.0 3.7 Notchecked None
T3 DCD 57 T 30 41 346 2.09 1.91 G 1920 7.6 — 25 5.9 8.1 Notchecked IC Awaitingretransplant
T4 DCD 63 T 20 31 222 2.08 2.09 G 1478 10.5 — 20 22.5 19.9 Notchecked None
T5 DCD 45 T 17 31 445 2.12 1.69 G 3783 9.2 — 30 >40 27.0 7.56 7.17 Notchecked None
T6 DCD 48 T 14 36 438 2.45 2.35 S 9490 4.6 — 35 9.5 8.6 Notchecked None Primarynonfunction
T7 DCD 55 T 11 30 396 2.51 2.03 S 1947 10.1 — 0 26.6 20.1 6.89 7.31 23.4 24.7 IC
T8 DBD 60 T 0 0 608 2.17 1.01 S 5576 10.6 — 0 31.5 24.0 7.85 7.30 3.5 20.5 None
T9 DCD 58 R 5 37 389 3.14 1.99 G 1118 21.5 11.6 40 38.4 30.1 7.57 7.24 7.0 22.0 None Researchofferbecauseoftraumaticinjurytoleft
lobe,mildlyfattyand“long”withdrawaltime
T10 DBD 39 R 0 0 618 1.47 0.96 G 418 14.0 13.3 0 8.5 6.3 7.84 7.20 1.8 14.1 None Researchofferbecauseofpoorinsituperfusion
T11 DCD 54 T 12 24 435 2.81 2.53 G 913 7.2 5.5 0 31.0 — 7.29 7.23 29.2 31.0 IC Retransplantd188forIC
T12 DBD 67 T 0 0 877 2.44 1.75 G 555 9.2 7.1 5 20.8 — Insufficientbile None Earlyallograftdysfunction:INR1.6onday7.
T13 DBD 71 T 0 0 245 2.00 1.15 G 4828 10.2 6.6 10 19.6 19.6 7.74 7.29 2.2 19.3 None
T14 DCD 69 T 10 51 383 3.57 2.20 G 486 11.7 16.3 0 9.4 7.9 7.69 7.48 Noreading None
T15 DBD 41 T 0 0 321 1.46 1.08 G 1377 10.1 6.2 5 14.4 — 7.53 7.07 Noreading None
T16 DCD 67 T 14 24 333 3.66 2.92 G 1753 7.7 5.8 5 12.1 13.8d 7.31 7.25 Noreading IC Retransplantday107forICandHAT
T17 DCD 43 T 12 23 330 2.67 1.95 G 1506 6.0 4.4 15 23.3 19.4 7.92 7.17 9.1 21.9 None
T18 DCD 66 T 13 24 448 3.17 2.24 G 2318 9.3 5.9 15 14.4 16.7d 7.72 7.23 2.6 15.5 None
T19 DCD 55 T 11 33 439 2.85 2.55 G 262 11.6 15.2 10 15.9 16.4 7.66 7.25 5.6 15.7 None
T20 DCD 29 T 10 16 292 1.69 1.43 G 216 12.6 5.6 15 18.6 17.4 7.62 7.39 2.1 18.7 None
T21 DBD 64 T 0 0 354 2.12 1.6 G 1906 9.0 8.1 10 17.5 18.3 7.89 7.28 3.8 18.3 None
T22 DCD 69 T 12 35 327 4.12 2.62 G 1631 5.8 4.9 10 21.6 15.7 7.72 7.27 5.8 13.4 None
R1 DCD 52 R 10 16 539 2.21 1.77 G 3561 7.8 — 20 8.3 8.2 Notchecked
R2 DCD 34 R 13 20 913 2.71 2.02 G 4385 3.8 4.2 0 22.8 — Notchecked
R3 DCD 39 R 16 27 523 1.69 1.39 G 8076 10.4 5.6 60 37.0 35.3 Notchecked
R4 DCD 46 R 12 420 264 1.84 1.42 G 3686 15.9 — 0 15.9 — Notchecked
R5 DBD 55 R 0 0 600 1.70 1.19 S 2561 15.0 10.3 15 33.8 — Notchecked
R6 DCD 64 R 10 21 384 3.60 2.26 S 740 6.7 4.1 5 24.6 18.5 Notchecked
R7 DCD 44 R 9 22 574 1.70 2.01 S 11970 10.7 5.5 0 14.7 12.2 Notchecked
R8 DCD 45 R 12 38 836 2.99 1.64 G 8348 6.8 4.5 0 10.6 7.2 Insufficientbile
R9 DCD 76 R 12 ? 611 3.14 2.38 G 1573 17.2 9.4 0 28.1 23.9 Insufficientbile
R10 DCD 44 R 8 12 261 2.11 2.02 G 2469 3.5 2.7 30 20.6 17.2 Noreading
R11 DCD 61 T 12 18 456 2.78 2.21 G 4616 6.2 4.0 10 18.5 — Insufficientbile 3 Nottransplanted:Leftlobenotperfuseddueto
dividedleftaccessoryhepaticartery
R12 DCD 69 R 11 21 764 2.70 2.60 G 3623 16.9 13.6 0 28.0 21.4 7.72 7.42 5.4 23.7 1 Unexplainedleftlobeatrophy
R13 DBD 44 R 0 0 1148 1.92 0.97 G 7254 8.8 4.2 20 34.8 27.4 7.38 7.22 32.2 32.6 4 Verysteatoticliver
R14 DCD 35 T 13 20 323 1.74 1.65 G 2648 12.4 8.3 0 15.8 — 7.47 7.10 6.4 14.2 4 NottransplantedduetolowbilepH
R15 DCD 47 R 11 11 686 2.62 1.71 G 5386 7.5 4.8 30 26.7 24.5 Hemobilia 1 Cysticductnotligated.Steatohepatitisonbiopsy
R16 DCD 66 T 8 26 518 3.31 1.91 G 2439 8.7 4.2 40 37.6 35.9 7.40 7.33 34.5 35.9 3/4 Nottransplanted:Poorglucosefall,slowlactatefall,
risingpotassiumandhighbicarbonateuse,lowbilepH
R17 DBD 81 R 0 0 466 2.37 1.71 G 346 12.3 11.5 0 23.4 28.8 Hemobilia 2
R18 DCD 49 T 11 30 482 2.81 1.81 G 694 17.3 10.1 15 21.1 18.5 7.31 7.19 18.3 21.9 4 Nottransplanted,lowbilepH
R19 DCD 59 T 12 32 306 2.68 1.97 G 4909 10.4 10 30.1 20.9 7.44 7.21 24.7 28.2 4 Nottransplanted,lowbilepH
R20 DBD 55 T 0 0 328 1.79 0.99 G 4294 6.8 3.0 20 16.6 9.8d 7.46 7.27 4.1 8.6 2 Nottransplanted,lowbilepH
R21 DCD 57 R 28 ? 467 3.36 2.49 G 4852 6.7 4.6 15 22.3 14.9 7.75 7.21 15.5 14.9 1
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R22 DCD 69 T 9 31 278 2.70 2.48 G 9613 10.2 6.3 10 29.0 28.1 7.61 7.21 22.2 28.1 1 Nottransplanted,highALT
R23 DCD 40 T 5 21 373 1.96 1.62 G 4424 10.8 6.2 20 32.6 29.3 Insufficientbile 3 Nottransplanted,highALT
R24 DCD 26 R 7 23 366 1.83 1.57 G 2413 9.6 3.9 25 17.6 13.8 7.75 7.15 6.1 11.9 1 2.8kgsteatoticliver,poorlyperfusedrightlobe
















































A Portal vein resistance






































B Hepatic artery resistance






















C Portal vein flows


























D Hepatic artery flows
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3.5.1 | Glycogenolysis
Toinvestigatewhethertheglucoserisecouldbeattributedtogly‐
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Amount of 
NaCO3 added in 
first 4 h (mmol)
Perfusate glucose 
(mmol/L)




















R22 DCD 69 T 9 31 278 2.70 2.48 G 9613 10.2 6.3 10 29.0 28.1 7.61 7.21 22.2 28.1 1 Nottransplanted,highALT
R23 DCD 40 T 5 21 373 1.96 1.62 G 4424 10.8 6.2 20 32.6 29.3 Insufficientbile 3 Nottransplanted,highALT
R24 DCD 26 R 7 23 366 1.83 1.57 G 2413 9.6 3.9 25 17.6 13.8 7.75 7.15 6.1 11.9 1 2.8kgsteatoticliver,poorlyperfusedrightlobe



































A ALT Transplanted livers


















C AST Transplanted livers

















B ALT non-transplanted livers


















D AST non-transplanted livers





of the resultingeffluent ranged from2.7 to22.1mmol/L (1.2 to
12.6mmol/L/kg),andwasproportional to thepeakglucosedur‐
ing NESLiP (Supplementary Figure 4, r=.72, P<.001), suggest‐
ingthattherateofglycogenolysiswasalsoproportional.Neither
effluent glucose nor peak glucosewere strongly related to cold
ischemictimepriortoNESLiP(r=−.11,P=.57foreffluent;r=.38,
P=.04forpeakglucose).Effluentglucoseshowedatrendtobeing
higher inDCD livers thanDBD livers (DBDmedian9.7, IQR5.5-
11.2;medianDCD12.2,IQR6.8-22.1mmol/L).
3.6 | Glucose challenge to interrogate a non- rising 
perfusate glucose
Two of the four livers which did not generate a perfusate glu‐








































A Relationship between the ALT in the perfusate at 2 hours and 
the ALT concentration in the effluent after flushing the liver
r = 0.776
p < 0.0001
x = transplanted liver
+= non-transplant liver



































B Relationship between the ALT in the perfusate at 2 hours 






















































































3.7 | Maintenance of perfusate pH





twohours. Three livers requiredmore than30mmolof bicarbonate,
oneofwhich(T6)wastransplantedandsufferedprimarynonfunction.
3.8 | Bile flow









not informativewith lossof superficial epitheliumbeing common,
presumably due to handling and cannulation artefacts. Therefore,
the technique of preparing research livers postperfusion was
changed to produce transverse sections through the hilumwhich
included septal ducts; 15 research liverswere treated in thisway
(Figure8).
The peri-biliary vascular plexus was rarely seen on H&E, and




identifiedusingaCD31 specific stain, and lossof capillaryCD31-
stainingcorrespondedtotheareasofstromalnecrosis.Eightlivers
showedgrade3or4 stromalnecrosis, twograde2 (oneofwhich


















Bicarbonate,which is actively secretedbycholangiocytes,13 and 






























T6: primary non function
A Transplanted livers
Glucose boluses given



























Validatedguidelines to assess liver functionandviabilityduring
normothermicex situ liverperfusiondonotexist.Theavailable










60minutesof perfusionbefore a steady state is reached.The re‐
sistancesdidnotappeartocorrelatewithoutcomeorbiochemical
markersofhepatocellularinjury.Resistanceiscommonlyusedasa
discriminator in hypothermic kidney perfusion, although evidence
for its predictive utility is poor.16,17 Similarly there is evidence in
hypothermic liverperfusion that resistancedoesnot reflectwarm
ischemicinjury.18
Lactate clearance is used clinically as a marker of immediate































































B Glucose bolus (liver R20)








thresholdwithin 90minutes.The rate of lactate fall per unit liver
weightmaybeamoreappropriatemeasureofhepatocellularfunc‐
tion. In addition, lactate concentrationmaybedeceptively high in
















mones,21 so may start at the time of treatment withdrawal in
DCDdonors,andconinginDBDdonors,timescharacterizedby
high levelsofsuchhormones; it isnoteworthythatglucose lev‐
elswerehigherinDCDdonorlivers.Lactateismetabolizedinto
glucoseinanoxygen-dependentprocessandthiswillcontribute
inpart to the raisedperfusateglucoseobservedat the startof 
NESLiP.22,23
The subsequent spontaneous fall in glucose during NESLiP
probably in large part represented glucose entering the liver
via the insulin-independentGLUT2bidirectional transporter,al‐





although its absencedoes not appear to havebeendeleterious
inourperfusions. Insulin isknownto inhibitglycogenolysisand
stimulateglycogenesis, buthighglucose concentrationsmaybe
a stronger stimulant at the levels seen duringmost perfusions,
andwehavedemonstratedglycogensynthesisintheabsenceof
exogenousinsulin(SupplementaryFigureS3).Inourinitialexper‐







that developed primary nonfunction.We subsequently demon‐
strated that interrogationwith a glucose challenge can demon‐
stratemetabolicactivity,andcommendthisasasimpletest.
Inthispaper, theperfusatetransaminaseconcentrationsrelate
to the 2-liter circuit, andmost liver perfusate concentrations had















































Research, Grade1/2 stromal necrosis
Research, Grade 3/4 stromal necrosis
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damageratherthanAST,sinceASTmayalsoarisefromhemolysis
onthecircuit.
We have shown that there is considerable transaminase re‐
leasepriortoNESLiP,witheffluentlevelscorrelatingcloselywith
the levels observed during perfusion.Measurement of effluent
transaminaseconcentrationsmaybeausefultesttoperformbe‐
fore transplantationwheneverconcernexistsabouta liver, and
maybeusefultoindicatethoseliverswherefurtherassessment
andmanipulationduringnormothermicperfusionmaybehelpful.
High concentrations of transaminase washing out of the liver
before NESLiP suggest that significant hepatocellular damage




















































tion affected outcome following transplantation. One liver that










takenas ahistologicalmarkerof irreversiblebileductdamage in
thisstudy,anditspresencewashighlightedbytheabsenceofcap‐
illariesstainingwithCD31.
Bile should normally contain little glucose, sincewhile can‐
alicular bile has a concentration similar to plasma, cholangio‐
cytes reabsorb glucose from bile resulting in a low glucose,14 
and this provided an additional marker of bile duct viability. A
bilepH<7.4andglucose<10mmol/L lowerthanperfusateglu‐
cose suggested significant stromal injury. Although it is possi‐
ble that low perfusate pHmay affect the ability to generate a
pH>7.5, this did not appear to be the case although high glu‐
cose gradients did pose more of a challenge to cholangiocyte




wewerenotable to include them inourprotocol.Theuseofbile
saltswillaffectbileproductionandmayaffectitspHandtheinci‐
denceofcholangiopathy,butinitialreportsfromamulticentertrial
where they were used suggest cholangiopathy also occurs even
whentaurocholateispresent(DavidNasralla,personalcommunica‐
tion).Perfusionsinexcessof8hoursintheabsenceofbilesaltshave
beenshowntoresult inbiliarydamage inpigs,29hencewe limited
ourperfusionstounder8hours.
The incidence of cholangiopathy in transplanted livers
(4/22=18%)andgrade3or4septalductstromalnecrosisinnon‐
transplanted livers (8/15=53%) suggests that NESLiP, per se,























Transplanted liver, ischaemic cholangiopathy
Transplanted liver, no cholangiopathy
Research liver, grade 3 or 4 stromal necrosis
Research liver, grade 1 stromal necrosis
Research liver, grade 2 stomal necrosis
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Research, Grade 1 stromal necrosis
Research, Grade 2 stromal necrosis
Research liver, Grade 3 or 4 stromal 
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A Changes in glucose concentration in bile during perfusion














































































) Transplanted liver with cholangiopathy
Research liver, grade 3 or 4 stromal necrosis
Research liver, grade 1 stromal necrosis
Research liver, grade 2 stromal necrosis
Transplanted liver, no cholangiopathy
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andwill be aided by our identification of biochemical markers of
cholangiocytedamage.
Otherbiochemicalobservations,nothighlighted,mayalsopro‐









syndrome has been discussed elsewhere.7 We evaluated Steen
solutionasa replacement forGelofusine in sixperfusionsbut it
wasmoreexpensiveandtheresultswerenotsuperior.Recognition
ofapossibleassociationofbiliarypHwithbileductdamagere‐
sulted inanumberof liversbeingdeclinedduetoa lowbilepH
andhighbileglucose.Table3showsthecriteriawecurrentlyuse
todeterminewhetherornottheliverissafetotransplant,butwe
fully acknowledge that early inour experiencewe turneddown
liversthatwewouldnowconsiderviable.Similarly,Table3isnot
meant to represent definitive criteria, but rather illustrates our
current“comfortzone.”
In summary, this report of the 47 normothermic perfusions
we have undertaken has identified patterns of biochemical re‐
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